Comparative Pharmacology
Head-to-head clinical analysis: AVANDAMET versus ROSIGLITAZONE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVANDAMET versus ROSIGLITAZONE MALEATE.
AVANDAMET vs ROSIGLITAZONE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVANDAMET combines rosiglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPARγ), and metformin, a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
Rosiglitazone is a thiazolidinedione that acts as a selective agonist at peroxisome proliferator-activated receptor-gamma (PPARγ). Activation of PPARγ increases insulin sensitivity in adipose tissue, skeletal muscle, and liver, leading to reduced hepatic gluconeogenesis and increased glucose uptake.
Oral, initial dose of rosiglitazone 4 mg/metformin 500 mg twice daily or rosiglitazone 2 mg/metformin 500 mg twice daily; maximum recommended dose rosiglitazone 8 mg/metformin 2000 mg per day.
4 mg orally once daily; may increase to 8 mg once daily after 12 weeks if inadequate glycemic response.
None Documented
None Documented
Rosiglitazone: 3-4 hours (terminal); metformin: 6.2 hours (terminal). No accumulation with normal renal function.
Terminal elimination half-life is 3-4 hours; clinically relevant as dosing is twice daily to maintain steady-state concentrations.
Renal (90-95% as unchanged drug for rosiglitazone; metformin is 90% renally eliminated unchanged). Biliary/fecal: minor (<5% for both).
Primarily hepatic metabolism via CYP2C8, with less than 1% excreted unchanged in urine. Fecal excretion of metabolites accounts for approximately 64% and renal excretion for 23% of the dose.
Category C
Category A/B
Thiazolidinedione and Biguanide Combination
Thiazolidinedione